Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Combining Intestinal Low Dose Radiotherapy Plus Tislelizumab and Chemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma

NCT07339488 is registered in ClinicalTrials.gov with Chuangzhen Chen as lead sponsor.

NCT NCT07339488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07339488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Combining Intestinal Low Dose Radiotherapy Plus Tislelizumab and Chemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
Lead sponsor
Chuangzhen Chen
Phase
Phase 2
Overall status
Recruiting
Start date
December 5, 2025
Completion date
October 30, 2029
Enrollment
39 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

borderline resectable carcinoma, chemotherapy, esophageal squamous cell carcinoma (escc), immune checkpoint inhibitor, radiotherapy, tislelizumab, unresectable cancer